tbuckley/cabot-search huggingface dataset:
The Centennial Year
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHLORINATED LIME AND CYSTS OF HUMAN INTESTINAL PARASITES
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and efficacy of intraperitoneal paclitaxel plus systemic FOLFOX for gastric cancer with peritoneal metastasis: Phase I results.
Authors: So Hyun Kang, Sa-Hong Min, Jin Won Kim, Eunju Lee, Sangjun Lee, Hyeon Jeong Oh, Young Suk Park, Yoon Jin Lee, Ji-Won Kim, Sang-Hoon Ahn, Yun-Suhk Suh, Keun-Wook Lee, Hye Seung Lee, Hyung-Ho Kim
Journal: Journal of Clinical Oncology (2022)

309 Background: Peritoneal metastasis (PM) still remains a major obstacle in the treatment of stage IV gastric cancer. This study was designed as a dose-escalation study of intraperitoneal (IP) paclitaxel combined with intravenous (IV) fluorouracil, leucovorin, and oxaliplatin (FOLFOX) to determine the recommended phase II dose in gastric cancer patients. Methods: Patients with gastric adenocarcinoma with PM were enrolled. Peritoneal cancer index (PCI) score was evaluated, and IP + IV chemoport insertion was done. The initial dose of IP paclitaxel was 40mg/m 2 , then stepped up to 60 then 80mg/m 2 . Target dose was 100mg/m 2 . IV FOLFOX was administered on the same day (oxaliplatin 100mg/m 2 , leucovorin 100mg/m 2 , fluorouracil 2400mg/m 2 ). Dose limiting toxicity (DLT) was defined as leukopenia ≥ grade 4, thrombocytopenia ≥ grade 3, febrile neutropenia ≥ grade 3, and other nonhematologic toxicity ≥ grade 3. Results: Fifteen patients were enrolled, and two patients were dropped due to patient consent withdrawal. There was no DLT at 40 and 60mg/m 2 doses. Two patients had grade 3 febrile neutropenia at dose 80mg/m 2 , and thus the final recommended phase II dose was 60mg/m 2 . Other patients underwent IP paclitaxel and FOLFOX without serious adverse events. Seven patients underwent second-look diagnostic laparoscopy, and the average change in PCI score was -5.6 ± 9.3. Four patients received gastrectomy, and the ascites conversion rate was 4/5 (80%). Median survival time was 16.6 months (95% CI, 7.2 – N/A). Conclusions: The biweekly regimen of IP paclitaxel and FOLFOX is safe and the recommended dose for a phase II trial is 60mg/m 2 . Clinical trial information: NCT03618758.
Outcomes of patients with small intestine adenocarcinoma (SIA) in a Canadian province: A population-based cohort study.
Authors: Emma Yanko, Duc Le, Shazia Mahmood, Nathan Ginther, Haji I. Chalchal, Rani Kanthan, Kamal Haider, Adnan Zaidi, Dueck Dorie-Anna, Shahid Ahmed
Journal: Journal of Clinical Oncology (2022)

641 Background: SIA is a rare cancer. Limited data is available about clinicopathological factors and interventions that correlate with its outcomes. The current study aims to determine outcomes of patients with SIA who were diagnosed in a Canadian province. Methods: In this retrospective population-based cohort study patients with biopsy proven SIA diagnosed during 2008-2017 in the province of Saskatchewan were assessed. A Cox Proportional multivariate regression analysis was performed to determine correlation between survival and exploratory factors. Results: 112 eligible patients with median age of 73 yrs and M:W 53: 59 were identified. 75% had a comorbid illness, 34% had a secondary cancer and 45% had WHO performance status (PS) &lt; 2. Of 112 patients, 51 (46%) had early-stage disease and 61 (54%) had advanced-stage disease. Median neutrophil: lymphocyte (NLR) was 4.5. The median overall survival (mOS) in relation to stage of the disease were as follow: stage 1, 59 months, stage 2, 30 months, stage 3, 20 months and stage 4, 3 months (P &lt; 0.001). The patients with early-stage disease had mOS of 36.0 months (95% CI: 8.0-64.0) vs. 3.0 months (1.74-4.26) with advanced disease (P &lt; 0.0001). Of 21 patients with stage 3 disease their median disease-free survival was 26 months (23.1-28.9) with chemotherapy vs. 4 months (0.0-9.1) with no chemotherapy, p = 0.04. Patients with stage 4 disease who had surgery and or chemotherapy had mOS of 18 months (13.70-23.32) vs. 4 months (2.20-5.82) with chemotherapy alone p = 0.03. On univariate analysis age ≥70 yrs, WHO PS &gt; 1, stage 4 disease, low albumin, elevated creatinine, high alkaline phosphatase, duodenal cancer, lack of surgery, and NLR of &gt; 4.50 were significantly correlated with inferior survival. On multivariate analysis stage 4 disease, HR, 3.20 (95%CI:1.84-5.40), WHO PS &gt; 1, HR, 2.22 (1.42-3.45), no surgery, HR, 2.10 (1.25-3.50), and NLR &gt; 4.5, HR, 1.72 (1.10-2.71) were significantly correlated with inferior survival. Conclusions: Most patients with SIA were diagnosed with advanced-stage. In addition to advanced-stage disease and poor PS, lack of surgery and baseline LNR of &gt; 4.5 were significantly correlated with inferior survival.
Infectious diseases surveillance update
Authors: Ruth Zwizwai
Journal: The Lancet Infectious Diseases (2015)

As of Feb 3, 2015, six cases of Guillain-Barré syndrome (GBS) were reported from Duleek, County Meath, Ireland; four cases have been confirmed and two are suspected. With a population of fewer than 6000 residents, Duleek should only have a 0·00001% chance of six people contracting the disease. The cause of the suspected cluster of the disease remains unknown; however, both the Health Service Executive and the Environmental Protection Agency are investigating the cause. Most confirmed cases of GBS are linked to a previous episode of infection, a vaccination, or a surgical intervention.
What Happened before Losses of Photosynthesis in Cryptophyte Algae?
Authors: Shigekatsu Suzuki, Ryo Matsuzaki, Haruyo Yamaguchi, Masanobu Kawachi
Journal: Molecular Biology and Evolution (2022)

Abstract In many lineages of algae and land plants, photosynthesis was lost multiple times independently. Comparative analyses of photosynthetic and secondary nonphotosynthetic relatives have revealed the essential functions of plastids, beyond photosynthesis. However, evolutionary triggers and processes that drive the loss of photosynthesis remain unknown. Cryptophytes are microalgae with complex plastids derived from a red alga. They include several secondary nonphotosynthetic species with closely related photosynthetic taxa. In this study, we found that a cryptophyte, Cryptomonas borealis, is in a stage just prior to the loss of photosynthesis. Cryptomonas borealis was mixotrophic, possessed photosynthetic activity, and grew independent of light. The plastid genome of C. borealis had distinct features, including increases of group II introns with mobility, frequent genome rearrangements, incomplete loss of inverted repeats, and abundant small/medium/large-sized structural variants. These features provide insight into the evolutionary process leading to the loss of photosynthesis.
Fedi-Fair
Authors: Edwin P. Brennan
Journal: JAMA (1975)

<h3>To the Editor.—</h3> With medical care recognized as a constitutional right, justice must now be provided every American citizen. Therefore, enactment of the National Just Service Act (Fedi-Fair) is being drafted by thoughtful California citizens in the spirit of that ancient Indian prayer, "Grant that I may not criticize my neighbor until I have walked a mile in his moccasins." The act should include the following provisions: Compensation for legal services will be based on the 1969 nationalaverage fees minus 28% (consistent with medical payments under Medicare and Medicaid). To provide speedy public trial, courts will operate 24 hours a day, 365 days a year (like hospitals). Legal-fee splitting, forwarding fees, and solicitation of clients constitute Fedi-Fair fraud, a felony. Justice being too important to be left in the hands of attorneys, each state bar will be reorganized with a majority of lay members. The
Table of Contents
Authors: Christina Wyatt, P Coates, Germaine Wong, Tilman Drueke, Brad Rovin, Pierre Ronco, Debasish Banerjee, Joyce Popoola, Sapna Shah, Irina Ster, Virginia Quan, Mysore Phanish, Federico Alberici, Elisa Delbarba, Chiara Manenti, Laura Econimo, Francesca Valerio, Alessandra Pola, Camilla Maffei, Stefano Possenti, Nicole Zambetti, Marianna Moscato, Margherita Venturini, Stefania Affatato, Mario Gaggiotti, Nicola Bossini, Francesco Scolari, Francois Alhenc-Gelas, Edward Siew, T Alp Ikizler, Joseph Chambers, Rebecca Wingert, Noémie Jourde-Chiche, Stéphane Burtey, Michelle Rheault, William Smoyer, Eric Rondeau, Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallee, Sung-Soo Yoon, David Kavanagh, Hermann Haller, Hassan Izzedine, Kenar Jhaveri, Mark Perazella, Andres Gomez-Aldana, Monica Tapias, Diego Rosselli, J Stratil, Adnan Sharif, Jan Zijlstra, Matijs Van Meurs, Jill Moser, Sarah Faubel, Sidharth Sethi, Rupesh Raina, Ronith Chakraborty, Vijay Kher, Ewa Elenberg, Christine O'mahony, Karen Eldin, Sandrine Lemoine, Dominique Eladari, Laurent Juillard, Amélie Bonnefond, Philippe Froguel, Laurence Dubourg, Marine Livrozet, Emmanuel Esteve, Michel Daudon, Jeremy Zaworski, Jean-Philippe Haymann, Vincent Frochot, Jean-Jacques Boffa, Dominique Bazin, Jean-Francois Benoist, Emmanuel Letavernier
Journal: Kidney International (2020)
A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy.
Authors: Hung-Yang Kuo, Jhe-Cyuan Guo, Ta-Chen Huang, Chia-Chi Lin, Jang-Ming Lee, Kun-Huei Yeh, Chih-Hung Hsu
Journal: Journal of Clinical Oncology (2022)

TPS364 Background: Patients with R/M ESCC failing platinum-based chemotherapy have grave prognosis. Anti PD-1 immune-checkpoint inhibitors (ICIs), by demonstrating survival benefits over 2 nd -line chemotherapy in multiple phase III trials, have emerged as a new standard-of-care for patients with platinum-refractory R/M ESCC. However, the efficacy of anti-PD-1 ICIs remains modest with an objective response rate (ORR) of 17-20%; and the median overall survivals (OS) for these patients range from 8.2 to 10 months. Cabozantinib, a multikinase inhibitor, in combination with atezolizumab has been investigated in the phase Ib COSMIC-021 trial, which includes multiple cohorts of various cancer types including gastroesophageal cancer and head-and-neck cancer. Promising preliminary results were reported in lung cancer and genitourinary cancer cohorts. To investigate the combination of cabozantinib plus atezolizumab in patients with ESCC, a subtype of esophageal cancer that may be under-represented in the gastroesophageal cancer cohort of COSMIC-021 trial, we thus proposed this phase II trial to verify the hypothesis whether adding cabozantinib to atezolizumab would improve the outcomes of R/M ESCC patients who have failed platinum-based chemotherapy. Methods: This single institution single-arm phase II study includes patients with histologically confirmed R/M ESCC who failed at least one platinum-based chemotherapy. Patients with prior exposure of any ICI or kinase inhibitor are excluded. Patients enrolled will receive cabozantinib 40mg once per day and atezolizumab 1200mg once every three weeks until disease progression or intolerable toxicities. The primary endpoint of this study is the ORR evaluated by RECIST 1.1; and the key secondary endpoints include progression-free survival, OS, and toxicity profile. We hypothesize that combination of cabozantinib plus atezolizumab will improve the ORR from 15% to 30%. With one-sided, 0.1 type I error (α), 0.2 type II error (β, corresponding power: 0.8), the sample size will be 37. The study, registered with clinical trial ID of NCT05007613, started patient enrollment in Jun 2021. As of Sep of 2021, 5 patients have been enrolled. Clinical trial information: NCT05007613.
α-Catulin promotes cancer stemness by antagonizing WWP1-mediated KLF5 degradation in lung cancer
Authors: Chia-Hao Tung, Meng-Fan Huang, Chen-Hsien Liang, Yi-Ying Wu, Jia-En Wu, Cheng-Lung Hsu, Yuh-Ling Chen, Tse-Ming Hong
Journal: Theranostics (2022)

Background: The cytoskeletal linker protein α-Catulin has been shown to be important for tumor progression in various cancers. However, its role in the regulation of cancer stemness remains unclear. Methods: Phenotypic effects of α-Catulin on the cancer stem cell (CSC)-like properties and metastasis were examined by in vitro sphere formation assay, migration assay, invasion assay, and in vivo xenografted animal models. Yeast two-hybrid assay, co-immunoprecipitation assay, and cycloheximide chase assay were performed to confirm the effect of α-Catulin on the WWP1-mediated degradation of KLF5. CPTAC and TCGA database were analyzed to determine the clinical association of α-Catulin, KLF5, and stemness-associated signatures in lung adenocarcinoma. Results: We report that α-Catulin increases cancer stem-like properties in non-small cell lung cancer (NSCLC). The expression of α-Catulin is elevated in tumor spheres compared to sphere-derived adherent cells and promotes the acquisition of cancer stemness characteristics in vitro and in vivo. Mechanistically, the interaction of α-Catulin and the C-terminal region of Kruppel-like transcription factor KLF5 results in the inhibition of WWP1-mediated degradation of KLF5. Accordingly, increased protein expression of KLF5 is observed in clinical specimens of lung adenocarcinoma with high expression of α-Catulin compared to specimens with low α-Catulin-expression. Knockdown of KLF5 abrogates α-Catulin-driven cancer stemness. α-Catulin is known to interact with integrin-linked kinase (ILK). Notably, an ILK inhibitor disrupts the α-Catulin-KLF5 interaction, promotes the degradation of KLF5, and decreases α-Catulin-driven cancer stemness. Importantly, we identify a CTNNAL1/ILK/KLF5 three-gene signature for predicting poor overall survival in patients with lung adenocarcinoma. Conclusions: These findings reveal a molecular basis of α-Catulin-enhanced KLF5 signaling and highlight a role for α-Catulin in promoting cancer stemness.
Contents of the approximate number system
Authors: Jack C. Lyons
Journal: Behavioral and Brain Sciences (2021)

Clarke and Beck argue that the approximate number system (ANS) represents rational numbers, like 1/3 or 3.5. I think this claim is not supported by the evidence. Rather, I argue, ANS should be interpreted as representing natural numbers and ratios among them; and we should view the contents of these representations are genuinely approximate.
Loss-of-function <i>SLC30A2</i> mutants are associated with gut dysbiosis and alterations in intestinal gene expression in preterm infants
Authors: Shannon L Kelleher, Samina Alam, Olivia C Rivera, Shiran Barber-Zucker, Raz Zarivach, Takumi Wagatsuma, Taiho Kambe, David I Soybel, Justin Wright, Regina Lamendella
Journal: Gut Microbes (2021)

Loss of Paneth cell (PC) function is implicated in intestinal dysbiosis, mucosal inflammation, and numerous intestinal disorders, including necrotizing enterocolitis (NEC). Studies in mouse models show that zinc transporter ZnT2 (SLC30A2) is critical for PC function, playing a role in granule formation, secretion, and antimicrobial activity; however, no studies have investigated whether loss of ZnT2 function is associated with dysbiosis, mucosal inflammation, or intestinal dysfunction in humans. SLC30A2 was sequenced in healthy preterm infants (26–37 wks; n = 75), and structural analysis and functional assays determined the impact of mutations. In human stool samples, 16S rRNA sequencing and RNAseq of bacterial and human transcripts were performed. Three ZnT2 variants were common (>5%) in this population: H346Q, f = 19%; L293R, f = 7%; and a previously identified compound substitution in Exon7, f = 16%). H346Q had no effect on ZnT2 function or beta-diversity. Exon7 impaired zinc transport and was associated with a fractured gut microbiome. Analysis of microbial pathways suggested diverse effects on nutrient metabolism, glycan biosynthesis and metabolism, and drug resistance, which were associated with increased expression of host genes involved in tissue remodeling. L293R caused profound ZnT2 dysfunction and was associated with overt gut dysbiosis. Microbial pathway analysis suggested effects on nucleotide, amino acid and vitamin metabolism, which were associated with the increased expression of host genes involved in inflammation and immune response. In addition, L293R was associated with reduced weight gain in the early postnatal period. This implicates ZnT2 as a novel modulator of mucosal homeostasis in humans and suggests that genetic variants in ZnT2 may affect the risk of mucosal inflammation and intestinal disease.
PRACTICAL NOTES.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Authors: Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, Jose Luis Gorriz, Fan Fan Hou, John J.V. McMurray, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink
Journal: Journal of the American Society of Nephrology (2021)

In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes.Adults with eGFR of 25-75 ml/min per 1.73 m2 and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo. Here, we conducted a prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR,30 ml/min per 1.73 m2) at baseline. The primary end point was a composite of time to ≥50% sustained decline in eGFR, ESKD, or kidney or cardiovascular death. Secondary end points were a kidney composite (same as the primary end point but without cardiovascular death), a composite of cardiovascular death or heart failure hospitalization, and all-cause death.A total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: -2 to 47%) reduction in the primary composite endpoint, and 29% (-2 to 51%), 17% (-53 to 55%), and 32% (-21 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-values were 0.22, 0.13, 0.63, and 0.95, respectively, comparing CKD stages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73 m2 per year in the dapagliflozin and placebo groups, respectively (P=0.005). Patients treated with dapagliflozin or placebo had similar rates of serious adverse events and adverse events of interest.Among patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.
PSMA-Targeted Radiotherapy Extends Survival
Journal: Cancer Discovery (2021)

A drug that delivers radioactive isotopes to cells expressing prostate-specific membrane antigen (PSMA) prolonged the lives of men with metastatic castrate-resistant prostate cancer, researchers reported at the 2021 American Society of Clinical Oncology Annual Meeting. If approved, 177Lu-PSMA-617 would be the first targeted radiopharmaceutical available for treating a common solid tumor, and the first therapy directed at PSMA.
Errors in Results
Authors: Steven Nissen
Journal: JAMA (2021)

Mark C. Petrie, MBChB; Subodh Verma, MD, PhD; Kieran F. Docherty, MBChB; Silvio E. Inzucchi, MD; Inder Anand, MD, Dphil; Jan Bělohlávek, MD, PhD; Michael Böhm, MD, PhD; Chern-En Chiang, MD, PhD; Vijay K. Chopra, MD; Rudolf A. de Boer, MD, PhD; Akshay S. Desai, MD, MPH; Mirta Diez, MD; Jaroslaw Drozdz, MD, PhD; Andre Dukát, MD, PhD; Junbo Ge, MD; Jonathan Howlett, MD, PhD; Tzvetana Katova, MD, PhD; Masafumi Kitakaze, MD, PhD; Charlotta E. A. Ljungman, MD, PhD; Béla Merkely, MD, PhD; Jose C. Nicolau, MD, PhD; Eileen O'Meara, MD; Pham Nguyen Vinh, MD, PhD; Morten Schou, MD, PhD; Sergey Tereshchenko, MD, PhD; Lars Køber, MD, DMSc; Mikhail N. Kosiborod, MD; Anna Maria Langkilde, MD, PhD; Felipe A. Martinez, MD; Piotr Ponikowski, MD, PhD; Marc S. Sabatine, MD, MPH; Mikaela Sjöstrand, MD, PhD; Scott D. Solomon, MD; Per Johanson, MD, PhD; Peter J. Greasley, PhD; David Boulton, PhD; Olof Bengtsson, PhLic; Pardeep S. Jhund, MBChB, MSc, PhD; John J. V. McMurray, MD